[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE479687T1 - Kinaseinhibitoren - Google Patents

Kinaseinhibitoren

Info

Publication number
ATE479687T1
ATE479687T1 AT05810353T AT05810353T ATE479687T1 AT E479687 T1 ATE479687 T1 AT E479687T1 AT 05810353 T AT05810353 T AT 05810353T AT 05810353 T AT05810353 T AT 05810353T AT E479687 T1 ATE479687 T1 AT E479687T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
kinases
kits
variables
compounds
Prior art date
Application number
AT05810353T
Other languages
English (en)
Inventor
Qing Dong
David Hosfield
Bheema R Paraselli
Nicholas Scorah
Jeffrey A Stafford
Michael Wallace
Zhiyuan Zhang
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35677430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE479687(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE479687T1 publication Critical patent/ATE479687T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AT05810353T 2004-10-15 2005-10-14 Kinaseinhibitoren ATE479687T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61930204P 2004-10-15 2004-10-15
US67969005P 2005-05-11 2005-05-11
PCT/US2005/037059 WO2006044687A2 (en) 2004-10-15 2005-10-14 Kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE479687T1 true ATE479687T1 (de) 2010-09-15

Family

ID=35677430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05810353T ATE479687T1 (de) 2004-10-15 2005-10-14 Kinaseinhibitoren

Country Status (6)

Country Link
US (2) US7713973B2 (de)
EP (1) EP1812439B2 (de)
JP (3) JP2008516973A (de)
AT (1) ATE479687T1 (de)
DE (1) DE602005023333D1 (de)
WO (1) WO2006044687A2 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035365A2 (en) * 2002-10-16 2004-04-29 Transport Systems, Inc. Monorail sortation system
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
RU2007122485A (ru) 2004-11-17 2008-12-27 Мийкана Терапьютикс Ингибиторы киназы
EP2354139A1 (de) * 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridine als Kinaseinhibitoren
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7232901B2 (en) * 2005-07-01 2007-06-19 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7442700B2 (en) * 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
RU2447889C2 (ru) * 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
US8163746B2 (en) * 2006-04-19 2012-04-24 Astellas Pharma Inc. Azolecarboxamide derivative
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
PT2041138E (pt) 2006-07-07 2014-10-07 Bristol Myers Squibb Co Inibidores de pirrolotriazina quinase
WO2008021859A1 (en) * 2006-08-09 2008-02-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP2061479A4 (de) 2006-09-05 2010-08-04 Bipar Sciences Inc Fettsäuresynthesehemmung durch parp-hemmer und behandlungsverfahren damit
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
AR063581A1 (es) * 2006-11-08 2009-02-04 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa
EP2114946A2 (de) * 2007-01-02 2009-11-11 Brystol-Myers Squibb Company Nützliches zwischenprodukt für die zubereitung bestimmter pyrrolotriazinverbindungen und verfahren zur herstellung des zwischenprodukts
DE602008003194D1 (de) * 2007-01-08 2010-12-09 Bristol Myers Squibb Co Nützliche zwischenprodukte für die zubereitung bestimmter pyrrolotriazinverbindungen und verfahren zur herstellung dieser zwischenprodukte
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CN101730699A (zh) * 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
WO2008131050A1 (en) * 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AU2008262291A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8304547B2 (en) * 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
JP2011503111A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
KR20100102637A (ko) * 2007-12-07 2010-09-24 바이파 사이언스 인코포레이티드 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료
PE20091074A1 (es) * 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
DE102007060172A1 (de) 2007-12-13 2009-06-25 Bayer Healthcare Ag Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102008035209A1 (de) 2008-07-29 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Triazolotriazine und Triazolopyrazine und ihre Verwendung
WO2009087381A1 (en) * 2008-01-08 2009-07-16 Merck Sharp & Dohme Ltd Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
WO2009097233A1 (en) * 2008-01-28 2009-08-06 Schering Corporation Imidazopyrazines as protein kinase inhibitors
AU2009215191A1 (en) 2008-02-13 2009-08-20 Gilead Connecticut, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
CN102164604A (zh) 2008-07-24 2011-08-24 百时美施贵宝公司 用作激酶调节剂的稠合杂环化合物
EP2344504B1 (de) * 2008-10-08 2014-06-04 Bristol-Myers Squibb Company Pyrrolotriazin-kinaseinhibitoren
TWI478922B (zh) 2008-12-08 2015-04-01 Gilead Connenticut Inc 作為脾臟酪胺酸激酶（Ｓｙｋ）抑制劑之咪唑並吡化合物
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
SG10201707798SA (en) * 2008-12-08 2017-10-30 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
NZ593096A (en) * 2008-12-19 2012-11-30 Bristol Myers Squibb Co Carbazole carboxamide compounds useful as kinase inhibitors
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
CA2752114C (en) * 2009-02-13 2017-06-20 Bayer Pharma Aktiengesellschaft Fused pyrimidines as akt inhibitors
EP2440204B1 (de) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nikotinamidverbindungen als kinasemodulatoren
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
WO2011088045A1 (en) 2010-01-12 2011-07-21 Ambit Biosciences Corporation Aurora kinase compounds and methods of their use
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
JP5093527B2 (ja) * 2010-02-10 2012-12-12 日本電気株式会社 複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路
US9562056B2 (en) 2010-03-11 2017-02-07 Gilead Connecticut, Inc. Imidazopyridines Syk inhibitors
KR20130094710A (ko) * 2010-04-14 2013-08-26 어레이 바이오파마 인크. Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
WO2011159857A1 (en) 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
KR101548443B1 (ko) 2011-02-23 2015-08-28 화이자 인코포레이티드 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN105473573B (zh) 2013-06-25 2018-03-16 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
CN105431137A (zh) 2013-07-30 2016-03-23 吉利德康涅狄格公司 Syk抑制剂的制剂
NZ715776A (en) 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
DK3076976T3 (da) 2013-12-04 2020-12-07 Kronos Bio Inc Fremgangsmåder til behandling af cancer
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
EP3137454A1 (de) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
CA2955180A1 (en) 2014-07-14 2016-01-21 Gilead Sciences, Inc. Combinations comprising entospletinib and a vinca-alkaloid for treating cancers
AU2015335703B2 (en) 2014-10-24 2020-05-21 Bristol-Myers Squibb Company Carbazole derivatives
MY188048A (en) 2014-10-24 2021-11-12 Bristol Myers Squibb Co Indole carboxamide compounds useful as kinase inhibitors
CN107108555B (zh) 2014-10-24 2020-12-01 百时美施贵宝公司 三环阻转异构体化合物
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
EA036851B1 (ru) 2015-11-02 2020-12-28 Янссен Фармацевтика Нв [1,2,4]триазоло[1,5-a]пиримидин-7-ильное соединение
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MD3394033T2 (ro) 2015-12-22 2021-04-30 Incyte Corp Compuși heterociclici ca imunomodulatori
CN107141293B (zh) * 2016-03-01 2022-09-23 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3504198B1 (de) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclische verbindungen als immunmodulatoren
UA125302C2 (uk) 2016-11-02 2022-02-16 Янссен Фармацевтика Нв Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2
WO2018083103A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
AU2017353313C1 (en) 2016-11-02 2022-06-09 Janssen Pharmaceutica Nv (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
UA126394C2 (uk) 2016-12-22 2022-09-28 Інсайт Корпорейшн Похідні бензоксазолу як імуномодулятори
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
ES2969536T3 (es) * 2017-06-30 2024-05-21 Beijing Tide Pharmaceutical Co Ltd Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso
KR102399996B1 (ko) 2017-08-25 2022-05-20 길리애드 사이언시즈, 인코포레이티드 Syk 억제제의 다형체
JP7474709B2 (ja) 2018-02-27 2024-04-25 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
CN112135824B (zh) 2018-03-30 2024-11-05 因赛特公司 作为免疫调节剂的杂环化合物
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
CN111018860B (zh) * 2018-10-10 2022-06-10 中国药科大学 吡咯并三嗪类化合物及其应用
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
JP7273172B2 (ja) 2018-10-31 2023-05-12 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태
EP3972695A1 (de) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituierte exo-methylen-oxindole als hpk1/map4k1-inhibitoren
JP2022544189A (ja) 2019-08-09 2022-10-17 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
CN115175734B (zh) 2019-09-30 2024-04-19 因赛特公司 作为免疫调节剂的吡啶并[3,2-d]嘧啶化合物
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of pd-1/pd-l1 inhibitor
CN115916782B (zh) * 2020-06-01 2024-08-13 南京瑞捷医药科技有限公司 化合物及其作为脾酪氨酸激酶抑制剂的应用
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB828847A (en) 1956-12-14 1960-02-24 Ilford Ltd Improvements in or relating to cyanine dyes
FR1242962A (fr) 1959-08-25 1960-10-07 Kodak Pathe Nouveau procédé pour la préparation de colorants sensibilisateurs de la série des cyanines et des mérocyanines et produits obtenus
JPS54110226A (en) 1978-01-25 1979-08-29 Bayer Ag Dye
DE2844606A1 (de) 1978-10-13 1980-04-24 Bayer Ag Heterocyclische farbstoffe
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
ATE315654T1 (de) 1995-12-18 2006-02-15 Sugen Inc Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
WO1999009160A1 (fr) 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Proteines de regulation de cycle cellulaire
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6143480A (en) 1998-09-03 2000-11-07 Fuji Photo Film Co., Ltd. Leuco dye and image recording medium containing the same
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US20050113460A1 (en) 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
ES2258459T3 (es) * 1999-05-21 2006-09-01 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas.
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
CA2379863A1 (en) 1999-07-21 2001-02-01 University Of Massachusetts Kinase blocking polypeptides and uses thereof
US6787545B1 (en) * 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
SK3822002A3 (en) 1999-09-21 2002-10-08 Astrazeneca Ab Quinazoline derivatives, process for the preparation thereof and their use
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
IL148489A0 (en) 1999-09-21 2002-09-12 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
KR100910488B1 (ko) 1999-12-24 2009-08-04 아벤티스 파마 리미티드 아자인돌
JP2003520855A (ja) 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ 化学的化合物
WO2001056993A2 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
JP4783532B2 (ja) 2000-02-05 2011-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋのインヒビターとして有用なピラゾール組成物
EP1209158A1 (de) 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Substitutierte beta-Carboline
EP1134221A1 (de) 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituierte beta-Carboline als lkB-Kinasehemmer
JP2001294772A (ja) 2000-04-10 2001-10-23 Fuji Photo Film Co Ltd 着色組成物、インクジェット用インク及びインクジェット記録方法
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
CZ20024120A3 (cs) 2000-06-28 2003-03-12 Astrazeneca Ab Substituované chinazolinové deriváty a jejich použití jako inhibitory
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
DK1320531T3 (da) 2000-08-10 2011-01-03 Pfizer Italia Srl Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
IL154747A0 (en) 2000-09-15 2003-10-31 Vertex Pharma Pyrazole derivatives and pharmaceutical compositions containing the same
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6867300B2 (en) † 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6455559B1 (en) 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
US20040019046A1 (en) 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
SI1337521T1 (sl) 2000-11-28 2006-12-31 Pfizer Prod Inc Soli izotiazol-4-karboksamida in njihova uporaba kot antihiperproliferacijska sredstva
FR2818278B1 (fr) * 2000-12-20 2003-02-28 Sod Conseils Rech Applic Inhibiteurs de kinases dependantes des cyclines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
EP1345941A1 (de) * 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Cyclin-abhängige kinase (cdk) und glycogen synthase kinase-3 inhibitoren
CA2432303C (en) 2000-12-21 2010-04-13 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
EA005528B1 (ru) 2001-05-14 2005-04-28 Пфайзер Продактс Инк. Тартраты 5,8,14-триазатетрацикло[10.3.1.02,11.04,9]гексадека-2(11),3,5,7,9-пентаена
US20050090498A1 (en) 2001-05-24 2005-04-28 Kiyohiro Samizu 3-Quinolin-2(1h)-ylideneindolin-2-one derivative
EP1412327A2 (de) 2001-05-30 2004-04-28 LG Biomedical Institute Inhibitoren von proteinkinase zur behandlung von krankheit
MXPA03010961A (es) 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ES2274035T3 (es) 2001-06-01 2007-05-16 Vertex Pharmaceuticals Incorporated Compuestos de tiazol utiles como inhibidores de proteina quinasas.
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
AU2002318367B2 (en) 2001-06-22 2006-09-28 The Procter & Gamble Company Fabric care compositions for lipophilic fluid systems
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
ES2274076T3 (es) 2001-07-19 2007-05-16 Pfizer Italia S.R.L. Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y su uso como agentes antitumorales.
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
WO2003012046A2 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US6916798B2 (en) 2001-08-03 2005-07-12 Vertex Pharmaceuticals Incorporated Inhibitors of GSK-3 and uses thereof
BR0211742A (pt) 2001-08-06 2004-08-24 Pharmacia Italia Spa Derivados de aminoisoxazole ativos como inibidores de cinase
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2003027075A2 (en) 2001-09-19 2003-04-03 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
WO2003024935A2 (en) 2001-09-19 2003-03-27 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
JP2005507922A (ja) 2001-09-19 2005-03-24 ファルマシア・コーポレイション 炎症の治療のための置換されたインダゾール化合物
MXPA04002682A (es) 2001-09-19 2004-06-18 Pharmacia Corp Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion.
IL160744A0 (en) 2001-09-26 2004-08-31 Pharmacia Italia Spa Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
US20040010027A1 (en) 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
CN100491372C (zh) 2001-12-24 2009-05-27 阿斯特拉曾尼卡有限公司 作为欧若拉激酶抑制剂的取代喹唑啉衍生物
US20050026868A1 (en) 2003-07-11 2005-02-03 Metcalf Chester A. Phosphorus-containing macrocycles
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2003078427A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
ATE365733T1 (de) 2002-03-15 2007-07-15 Vertex Pharma Zusammensetzungen brauchbar als protein-kinase- inhibitoren
AU2003220299A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azinylaminoazoles as inhibitors of protein kinases
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
AU2003230802B2 (en) 2002-04-08 2007-08-09 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2003087395A2 (en) 2002-04-15 2003-10-23 Inserm Methods to identify anti-tumoral agents inhibiting rasgap / aurora kinase interactions
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003231232A1 (en) 2002-05-01 2003-11-17 Vertex Pharmaceuticals Incorporated Crystal structure of aurora-2 protein and binding pockets thereof
BR0311291A (pt) 2002-05-17 2005-03-29 Pharmacia Italia Spa Derivados de aminoindazol ativos como inibidores da cinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos
WO2003101983A1 (fr) 2002-05-31 2003-12-11 Yamanouchi Pharmaceutical Co., Ltd. Derive tetrahydropyrane
WO2003107002A1 (ja) 2002-06-12 2003-12-24 株式会社アクシアバイオサイエンス ｃｈｆｒタンパク質により触媒されるオーロラキナーゼＡ及びオーロラキナーゼＢのポリユビキチン化反応
FR2840905B1 (fr) 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
AU2003276005B2 (en) 2002-06-14 2009-01-15 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
EP1554269A1 (de) 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazole, oxazole und thiazole mit proteinkinasehemmenden wirkungen
AU2003253880A1 (en) 2002-07-15 2004-02-02 Sugen, Inc. Novel kinases
WO2004007504A1 (en) 2002-07-17 2004-01-22 Pharmacia Italia S.P.A. Heterobicyclic pyrazole derivatives as kinase inhibitors
EP1526852A1 (de) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
US20060135508A1 (en) 2002-07-25 2006-06-22 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1530573B1 (de) 2002-07-25 2008-03-19 Pfizer Italia S.r.l. Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
ES2293015T3 (es) * 2002-09-23 2008-03-16 Schering Corporation Imidazopirazinas como inhibidores de cinasas dependientes de ciclinas.
US20040157804A1 (en) 2002-10-16 2004-08-12 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
US6909001B2 (en) 2002-12-12 2005-06-21 Pharmacia Corporation Method of making tricyclic aminocyanopyridine compounds
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
WO2004056812A1 (en) 2002-12-23 2004-07-08 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
EP1575946A1 (de) 2002-12-24 2005-09-21 AstraZeneca AB Chinazoline verbindungen
WO2004058782A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Therapeutic quinazoline derivatives
BRPI0317717B8 (pt) 2002-12-24 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e uso de um composto
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
EP1590334B1 (de) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
US20050266409A1 (en) 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
ATE429228T1 (de) 2003-02-14 2009-05-15 Serono Lab Derivate von piperazine-2-carboxamide
WO2004071507A1 (en) 2003-02-17 2004-08-26 Pharmacia Italia S.P.A. Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ES2287583T3 (es) 2003-02-26 2007-12-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Dihidropteridinonas, procedimiento para su preparacion y su uso como medicamenteos.
EP1608364A1 (de) 2003-03-11 2005-12-28 Pharmacia Italia S.p.A. Bicyclische pyrazolderivate als kinasehemmer, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen damit
JP4808154B2 (ja) 2003-03-13 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用な組成物
EP1608631A4 (de) * 2003-03-28 2008-08-20 Scios Inc Bicyclische pyrimidininhibitoren von tgf beta
EP1608652A1 (de) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidinverbindungen und deren verwendung in der medizin
WO2004090106A2 (en) 2003-04-04 2004-10-21 Vertex Pharmaceuticals Incorporated Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design
BRPI0409427A (pt) 2003-04-16 2006-04-18 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
CA2522431A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
US7414055B2 (en) 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
CA2522262A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
CA2522430A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
US20040242559A1 (en) 2003-04-25 2004-12-02 Aventis Pharma S.A. Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
KR20060022649A (ko) 2003-05-01 2006-03-10 브리스톨-마이어스 스큅 컴퍼니 키나아제 억제제로서 유용한 아릴 치환 피라졸-아미드화합물
MXPA05011741A (es) 2003-05-01 2006-05-12 Univ Michigan Composiciones y metodos que se relacionan con compuestos y objetivos novedosos de los mismos.
US20050125852A1 (en) 2003-05-09 2005-06-09 Sugen, Inc. Novel kinases
JP5043432B2 (ja) 2003-05-22 2012-10-10 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピラゾロ−キナゾリン誘導体、その製造方法、およびキナーゼ阻害剤としてのその使用
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
ATE401080T1 (de) 2003-06-02 2008-08-15 Astrazeneca Ab (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
TW200505452A (en) 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
CA2528771A1 (en) 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
US20050065171A1 (en) 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
US20060178318A1 (en) 2003-07-03 2006-08-10 Shubha Anand Use of aurora kinase inhibitors for reducing the resistance of cancer cells
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315657D0 (en) 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
DE602004019530D1 (de) 2003-07-03 2009-04-02 Euro Celtique Sa 2-pyridin alkyne derivaten und ihre verwendung für die schmerzbehandlung
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0315966D0 (en) 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
PL1658292T3 (pl) 2003-07-16 2008-01-31 Janssen Pharmaceutica Nv Pochodne triazolopirymidyny jako inhibitory kinazy 3 syntazy glikogenu
EA011300B1 (ru) 2003-07-16 2009-02-27 Янссен Фармацевтика Н.В. Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3
WO2005012280A1 (en) 2003-07-21 2005-02-10 Applied Research Systems Ars Holding N.V. Alkynyl aryl carboxamides
ATE430741T1 (de) 2003-07-24 2009-05-15 Euro Celtique Sa Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
US20050026984A1 (en) 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2533870A1 (en) 2003-07-30 2005-02-10 Shudong Wang Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
JP2007500179A (ja) 2003-07-30 2007-01-11 サイクラセル・リミテッド キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン
US7094791B2 (en) 2003-07-31 2006-08-22 Avalon Pharmaceuticals, Inc. Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
AU2004267094A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
EP1667995A1 (de) 2003-09-12 2006-06-14 Applied Research Systems ARS Holding N.V. Benzimidazolacetonitrile
CA2538884C (en) 2003-09-16 2010-09-21 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US20070032513A1 (en) 2003-09-16 2007-02-08 Hennequin Laurent F A Quinazoline derivatives
WO2005026156A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
MXPA06003110A (es) 2003-09-17 2006-06-20 Icos Corp Uso de inhibidores de chk1 para controlar la proliferacion celular.
CA2539064A1 (en) 2003-09-17 2005-04-21 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
CA2537325A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
JP3962425B2 (ja) 2003-10-14 2007-08-22 ファルマシア・コーポレーション 炎症治療用置換ピラジノン化合物
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
SI1678166T1 (sl) 2003-10-14 2009-10-31 Univ Arizona State Inhibitorji proteinske kinaze
WO2005040159A1 (en) 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
WO2005037797A1 (en) 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
WO2005042525A1 (en) 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy
EP1678146A1 (de) 2003-10-23 2006-07-12 Pharmacia Corporation Pyrimidinverbindungen zur behandlung von entzündungen
WO2005044270A1 (en) 2003-11-04 2005-05-19 4Sc Ag Oxadiazolopyrazine derivatives as pharmaceutically active compounds
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2007521331A (ja) 2003-11-19 2007-08-02 シグナル ファーマシューティカルズ，エルエルシー 複数キナーゼの標的化による疾患及び障害の治療方法
FR2864084B1 (fr) 2003-12-17 2006-02-10 Aventis Pharma Sa Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
FR2876377B1 (fr) 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
JP2008542433A (ja) 2005-06-09 2008-11-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＣＤＫ−１インヒビターとしてのα−カルボリン
US7442700B2 (en) * 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors

Also Published As

Publication number Publication date
WO2006044687A2 (en) 2006-04-27
US7713973B2 (en) 2010-05-11
WO2006044687A3 (en) 2006-07-20
JP2012102121A (ja) 2012-05-31
JP2013121966A (ja) 2013-06-20
US8288536B2 (en) 2012-10-16
EP1812439B1 (de) 2010-09-01
EP1812439A2 (de) 2007-08-01
US20060084650A1 (en) 2006-04-20
JP2008516973A (ja) 2008-05-22
EP1812439B2 (de) 2017-12-06
JP5524171B2 (ja) 2014-06-18
DE602005023333D1 (de) 2010-10-14
US20100216765A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
ATE479687T1 (de) Kinaseinhibitoren
MY146989A (en) Kinase inhibitors
TN2010000131A1 (en) Polo-like kinase inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
WO2007117995A3 (en) Kinase inhibitors
WO2007028135A3 (en) Imidazopyridine compounds
WO2007075847A3 (en) Glucokinase activators
WO2008055236A3 (en) Mapk/erk kinase inhibitors
WO2007061923A3 (en) Glucokinase activators
JO2985B1 (ar) مثبطات كينازmapk/erk
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
TNSN08191A1 (en) Kinase inhibitors
WO2008115890A3 (en) Mapk/erk kinase inhibitors
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
NO20091817L (no) Kinase inhibitorer
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TN2009000151A1 (en) Mapk/erk kinase inhibitors
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties